Events 2012 ASCO Annual Meeting McCormick Place, Chicago June 1-5, 2012 Schedule a Meeting 2012 ACORN Network PI Meeting The Westin Memphis, Beale Street March 2-3, 2012 2011 ACORN Network PI Meeting The Westin Memphis, Beale Street February 10-12, 2011 2010 ASCO Annual Meeting McCormick Place, Chicago June 4-8, 2010

News Clarient and ACORN Research Announce a Collaboration to Standardize Testing of Most Common Cancers Partnership Will Offer Standardized Molecular Profiling to Improve the Link Between Testing and Treatment ALISO VIEJO, Calif.--(BUSINESS WIRE)--Clarient, Inc., a GE Healthcare company (NYSE:GE), and ACORN Research LLC announced today their strategic collaboration around molecular testing of tumor samples. The agreement will establish a standardized testing protocol across the ACORN network of oncology community practices and hospitals with treatment guidelines and clinical trial opportunities. These processes have the potential to improve oncology treatment and research that aim to deliver targeted treatments based on the specific genetic markers for each patient. “We are delighted to enter into this agreement with Clarient, a company which shares our commitment to improving patient outcomes in community oncology, where 85% of all cancer patients are treated” The collaboration will establish a system for the collection of a broad array of tumor-specific biomarker data at the time of the patient’s initial cancer diagnosis. Clarient’s expertise in cancer diagnostics, combined with ACORN’s oncology network and advanced bioinformatics platform, will enable the patient’s medical team to better determine the most effective treatment regimen for the patient’s tumor-specific biomarker profile. The Clarient-ACORN collaboration will also enable matching broad biomarker data with outcomes data from clinical trials and clinical practice to help identify new prognostic markers and biomarker-specific treatments. Molecular profiling will be the topic of numerous conversations as both the San Antonio Breast Cancer Symposium and the American Society of Hematology get underway this week. “As part of our commitment to take cancer personally, we are pleased to be working together with ACORN Research to provide oncologists within their network with a full menu of molecular testing, which can help identify the unique characteristics or biomarkers of a particular cancer. This information provides pathologists with crucial information to assist oncologists in diagnosis, prognosis and treatment planning,” said Ron Andrews, CEO of Clarient. “Also, the opportunity to discover new markers that could be relevant in the individualized treatment of cancer has the potential to improve mortality rates, enhance patient quality of life and reduce the cost burden on cancer treatment to both patients and payers.” “We are delighted to enter into this agreement with Clarient, a company which shares our commitment to improving patient outcomes in community oncology, where 85% of all cancer patients are treated,” said Lee Schwartzberg, MD, President of ACORN Research. “Our collaboration is a leap forward in bringing the most advanced diagnostics and bioinformatics tools to accelerate the use of personalized medicine in this setting.” About Clarient, Inc. Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. Clarient's principal customers include pathologists, oncologists, hospitals, and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing advanced oncology testing and diagnostic services. Clarient's customers are connected to its Internet-based portal, PATHSITE® that delivers high-resolution images and critical interpretive reports based on its diagnostic testing. Clarient also develops and markets new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung, ovarian, and colon cancers, and leukemia/lymphoma. For more information, visit www.clarientinc.com. About ACORN Research LLC ACORN Research, LLC is a multi-faceted research organization that combines a network of committed oncology research sites with centralized site management, a unique bioinformatics platform that combines the complete EMR record with patient reported outcomes in support of health outcomes research in oncology [Health Outcomes PharmacoEconomics Service Line (HOPE)], and a Contract Research Organization [CRO] capable of performing full study management into one seamless research operation. ACORN Research, LLC includes an infrastructure of medical oncologists, doctoral level scientists, statisticians, and other professional staff with many years of oncology specific research experience. www.acornresearch.net. Contacts GE Healthcare Aleisia Gibson 609-514-6046 (office) 609-865-4004 (mobile) Aleisia.gibson@ge.com or Scott Lerman 609-514-6346 (office) 609-937-9352 (mobile) scott.lerman@ge.com or ACORN Research Donna McDonnell 901-260-9284 (office) dmcdonnell@acornresearch.net ACORN Research, LLC Announces Partnership with AdeptBio, LLC MEMPHIS, TN., November 10, 2011 — ACORN Research has expanded its research footprint to support advances in personalized medicine and translational research, by offering high-quality biospecimens coupled with unprecedented premium data to industry and academic research through its partnership with AdeptBio, LLC (http://www.adeptbio.com).  ACORN Research is able to provide CRO services as needed to facilitate prospective collections of biospecimens from targeted study populations. “Development of new targeted therapies and companion diagnostics rely on availability of tissues, and increasingly biofluids, linked to deep clinical data. Banked samples are less able to meet this need, and therefore our model is aimed at optimizing prospective collections,” reports Dr. Lee Schwartzberg, president of ACORN Research. Leif Honda, AdeptBio, LLC, CEO, adds, “Researcher’s needs are changing as biomarkers and companion diagnostics emerge along with new regulatory requirements. AdeptBio’s relationship with ACORN Research presents an end-to-end answer to meet those needs. We are delighted to be entering into this partnership with ACORN Research as a CRO with an excellent history of success with its clients and rapport with their oncology network." ACORN Research and AdeptBio are committed to helping the research community make significant advancements in the prevention, diagnosis, and treatment of cancer, through the provision of relevant, leading edge biospecimens and associated data. About ACORN Research, LLC ACORN Research, LLC is a multi-faceted research organization that combines a network of committed oncology research sites supported by centralized research processes; a bioinformatics platform that joins EMR data with ePRO data to support health outcomes research and clinical trial efficiencies; and a contract research organization focused exclusively on oncology. We offer high quality biospecimens and biofluids using unmatched sophistication in donor services. About AdeptBio, LLC AdeptBio, LLC is a human biospecimen contract procurement organization formed through a partnership between experts in specimen procurement, contract research, biomarker discovery, diagnostics and therapeutic R&D. AdeptBio addresses the dramatically underserved needs of pharmaceutical and diagnostic R&D companies by overcoming the challenges of supply constraints, quality, consistency, and sample diversification. The company offers complete transparency in acquisition and accrual rates across a robust network providing thorough patient data and sample characterization, and the option for longitudinal access to information. The goal of the company is to meet increasing regulatory demands by providing the most complete medical information available to researchers. To learn more, visit http://www.acornresearch.net. Contact: Donna McDonnell ACORN Research, LLC 901.260.9284 dmcdonnell@acornresearch.net http:www.acornresearch.net     MBJ Presents Health Care Heroes Award Winners Memphis Business Journal Date: Wednesday, August 31, 2011, 7:26am CDT Memphis Business Journal held its 13th annual Health Care Heroes awards event last night, honoring the program's 20 finalists, five winners and lifetime achievement award recipient. The winners in each category are: Administrative Excellence: Reginald W. Coopwood, president and CEO, Regional Medical Center at Memphis Community Outreach: Le Bonheur Early Intervention and Development, Le Bonheur Children's Hospital Health Care Innovations: Lee Schwartzberg, senior partner and medical director, The West Clinic Health Care Provider Non-Physician: Renee S. Frazier, CEO, Healthy Memphis Common Table Health Care Provider Physician: William Hickerson, Medical director, Firefighters Regional Burn Center; Professor of plastic surgery, University of Tennessee Health Science Center; Chief of burn surgery, UT Medical Group Inc. and UTHSC Marion Dugdale received the lifetime achievement recognition. Dugdale — director of the University of Tennessee Health Science Center Hemophilia Clinic — boasts a hematology career that spans nearly six decades. Click here to view a slideshow of all the 2011 Health Care Heroes finalists. Click here to view full MBJ article.